Byondis’ Post

Check out the latest publication from Brandon Ruotolo and his group: “Ion Mobility-Mass Spectrometry and Collision Induced Unfolding Reveal Linker-Payload Effects on Antibody-Drug Conjugate Higher-Order Structure and Stability." https://lnkd.in/ekPHwpby #MichiganChemistry #MichiganChem #Chemistry #Michigan #UMich #MichiganResearch #ChemistryResearch #ScientificResearch #Research #STEM

🔬 A new mini review by Mia Zol‑Hanlon and Neil Q. McDonald explores recent progress in defining RET (REarrangement during Transfection) receptor architecture and structure. The review also discusses current models for how distinct assemblies of GFL–GFRα–RET receptor complexes activate the intrinsic RET tyrosine kinase to relay intracellular signals. The structural and mechanistic insights described are enabling new approaches to targeting RET, potentially expanding the repertoire of molecules and biologics available to treat RET‑driven disease. 📖 Read the review: https://lnkd.in/ez6JV4ua 🌟 This paper forms part of the themed collection RET@Thirty: Three Decades of Remarkable Progress.

**IRO + Synecta delivers step change in CAR-T productivity** Dig into the data in Blue Whale’s poster. The results of combining two next generation manufacturing technologies marks a significant shift in our ability to drive down COGs and vein to vein times. https://lnkd.in/eigiHqRu …

𝗔𝘂𝘁𝗼𝗺𝗮𝘁𝗶𝗼𝗻 𝗶𝘀 𝗼𝗻𝗹𝘆 𝗮𝘀 𝗴𝗼𝗼𝗱 𝗮𝘀 𝘁𝗵𝗲 𝗯𝗶𝗼𝗹𝗼𝗴𝘆 𝗶𝗻𝘀𝗶𝗱𝗲 𝗶𝘁. At #ISCT2026, Chiquita Hanindya will present data showing how Synecta™ T1 enables consistent, high-efficiency cell therapy manufacturing within a closed, automated workflow. Key findings:  • Higher transduction efficiency vs. polymeric nanomatrix beads  • Increased total viable transduced T cells  • Reduced process complexity (Day 0 activation/transduction, no soluble cytokines) Synecta is the unlock for automated cell therapy manufacturing to deliver on its promise. 📍 ISCT Dublin | 7 May 18:00 PM | Poster #1163

Three years ago, our R&D team set out to solve a problem the global #ADC industry has been grinding on for over a decade: how to tether a cytotoxic payload to an antibody so it stays stable in circulation — and releases precisely at the tumor. We received the answer in writing. Taiwan's Intellectual Property Office has granted AMS BioteQ (TWSE: 6864) the patent for our #TenTacle™ linker conjugate technology — the core architecture behind our ADC platform. (App. No. 112149200, IPC A61P 35/00, US priority 63/476,157.) What TenTacle™ brings: — High water solubility and structural stability, addressing the aggregation issues that have limited many ADC candidates — Non-cytotoxic linker design, widening the therapeutic safety window — Multivalent architecture, compatible with our proprietary fungal-derived compounds YUAN-01 and YUAN-03, targeting breast and lung cancers In ADC development, the bottleneck has never been the antibody or the payload — it has been the linker. Owning a differentiated, patent-protected one moves us from downstream participant to holder of infrastructure the field needs. TenTacle™ now opens the licensing platform — international partnerships running in parallel with our own pipeline. #ADC #Biotech #Oncology #AMSBioteQ

Three years ago, our R&D team set out to solve a problem the global #ADC industry has been grinding on for over a decade: how to tether a cytotoxic payload to an antibody so it stays stable in circulation — and releases precisely at the tumor. We received the answer in writing. Taiwan's Intellectual Property Office has granted AMS BioteQ (TWSE: 6864) the patent for our #TenTacle™ linker conjugate technology — the core architecture behind our ADC platform. (App. No. 112149200, IPC A61P 35/00, US priority 63/476,157.) What TenTacle™ brings: — High water solubility and structural stability, addressing the aggregation issues that have limited many ADC candidates — Non-cytotoxic linker design, widening the therapeutic safety window — Multivalent architecture, compatible with our proprietary fungal-derived compounds YUAN-01 and YUAN-03, targeting breast and lung cancers In ADC development, the bottleneck has never been the antibody or the payload — it has been the linker. Owning a differentiated, patent-protected one moves us from downstream participant to holder of infrastructure the field needs. TenTacle™ now opens the licensing platform — international partnerships running in parallel with our own pipeline. #ADC #Biotech #Oncology #AMSBioteQ

It’s exciting to see the ecosystem thriving! As cell therapy moves from cutting edge research into real world industrialization, the role of lighting and environmental conditions in high end biopharmaceutical laboratories and cleanrooms is becoming increasingly critical.

𝗛𝗲𝗮𝗱𝗶𝗻𝗴 𝘁𝗼 𝗜𝗦𝗖𝗧 𝟮𝟬𝟮𝟲 𝗶𝗻 𝗗𝘂𝗯𝗹𝗶𝗻? 🇮🇪 If you're working on: ✔️ Scaling adherent or suspension cultures ✔️ Reducing open handling and contamination risk ✔️ Moving toward GMP-ready, closed workflows Come visit our colleagues Ruud Das, Emma Kerklingh and Claire Pappers at booth #1415 for a live demo of Osilaris™! 📊 We’ll also be presenting our newest posters: #1506 – hiPSC expansion across multiple passages #1425 – HEK293T expansion for LVV manufacturing 🎤 Elevator pitch (May 7, 16:00, Forum Global Showcase): Closed, suspension-based hiPSC expansion in the Osilaris™ bioreactor Looking forward to connecting and discussing process intensification, closed manufacturing, and scale-out strategies in cell therapy. See you in Dublin! #ISCT2026

Really excited for #ISCT2026 this year! We will have the Osilaris bioreactor platform live at booth 1415 for demos, and I will be giving an elevator pitch on how we use Osilaris for closed, suspension-based hiPSC expansion on May 7 at 16:00. I will be sharing a short preview of some beautiful work from Juda-El Sam, focused on a closed, aggregate-based approach where single cells repeatedly form spheroids in suspension and what this could mean for more scalable, automated manufacturing of iPSCs. If you are working on MSC, iPSC or T-cell processes and want to see our bioreactor platform running, I hope to see you in Dublin!

Cells can sometimes accept mitochondria from outside. The hard part is delivery. A new Cell paper tested mitochondria packed into protective capsules. The capsule helps the organelle reach damaged cells instead of getting degraded on the way in. In mitochondrial disease and Parkinson's models, that improved energy function. Still preclinical, but the framing is interesting: organelle therapy, not another small molecule. Source: https://lnkd.in/eaKMJA3x